AlphaNavi Pharma Inc., was introduced in the case study of leading university-originated venture businesses’ efforts for team building, published by the Ministry of Economy, Trade, and Industry.
AlphaNavi Pharma Inc., (Head Office: Kyoto, Japan; CEO: Yoshihiro Oyamada), which is a start-up company to develop a novel and innovative analgesic drug for patients suffering from chronic pain, was introduced in the surveillance report on university-originated venture businesses, published by the Ministry of Economy, Trade, and Industry (METI).
In the surveillance report on university-originated venture businesses, METI compiled a variety of successful cases of University-Originated Venture Businesses. University based biotech companies are expected to play a leading role in bringing about innovation in the economy and society by implementing state of the art university-originated technologies. The survey by METI is being conducted to study the snapshots of the start-up companies’ foundations and investigate the surrounding business environments and needs to provide growth driving factors for future development of political measures. This FY2019 survey revealed that the number of such venture businesses (VBs) was 2,566 as of September 2019, showing an increase by 288 from 2,278 confirmed in FY2018 and reaching a record-high growth. METI considers it necessary to carefully watch the impact of expansion of the novel coronavirus disease on such VBs. In addition to this report, METI compiled a Collection of Case Examples of Leading University-Originated Venture Businesses’ Efforts for Team Building, focusing on team building, which is a key effort for business growth of such VBs.
Dr. Oyamada, CEO of AlphaNavi Pharma, said that it was honorable to be introduced to the survey report by METI.
(Ref. Ministry of Economy, Trade, and Industry website)
Ministry of Economy, Trade, and Industry website
https://www.meti.go.jp/press/2020/05/20200515003/20200515003.html